Belimumab in the treatment of systemic lupus erythematosus and other conditions
Authors:
H. Ciferská 1; D. Tegzová 1; J. Vachek 2
Authors‘ workplace:
Revmatologický Ústav, Praha a Revmatologická klinika 1. LF UK, Praha
1; Nefrologická klinika, Všeobecná fakultní nemocnice 1. LF UK, Praha
2
Published in:
Čes. Revmatol., 22, 2014, No. 4, p. 124-132.
Category:
Original Papers
Overview
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that blocks the binding of soluble BLyS (soluble B lymphocyte stimulator) on B lymphocytes. Belimumab is the first drug of biological nature approved by the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency) for the treatment of systemic lupus erythematosus (SLE). To date, it is intended for patients without renal or neurological manifestations of SLE. Belimumab has also been tested in other autoimmune diseases (Sjögren's syndrome, ANCA-associated vasculitis) and other conditions. This work aims to provide clear information about belimumab (pharmacological properties, indications and clinical studies), and demonstrate its efficacy in the treatment of SLE using a case report.
Key words:
Belimumab, biological therapy, systemic lupus erythematosus, BLyS, rheumatoid arthritis, Sjögren's syndrome, ANCA associated vasculitis
Sources
1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48 (11): 3253–65.
2. Stohl W. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun 2005; 8: 289–304.
3. Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009; 53 (1): 1–16.
4. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006; 65 (Suppl 3): 34–6.
5. Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 2006; 107(7): 2882–8.
6. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011; 91 (10): 1057–64.
7. Mariette X1, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2013 doi:10.1136/annrheumdis-2013-203991
8. Domsic RT, Ramsey-Goldman R, Manzi S. Epidemiology and classification of systemic lupus erythematosus. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 4th ed. Philadelphia (PA): Mosby-Elsevier; 2008: 1211–6.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40 (9): 1725.
10. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011; 13(4): 228.
11. Tengner P, Halse AK, Haga HJ. Detection of anti-Ro/SSA and antiLA/SSB. autoantibody-producing cells in salivary glans of patients with Sjögren’s syndrome. Arthtitis Rheum 1998; 41: 2238–2248.
12. Vitali C1, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE at al. Classification criteria for Sjögren ’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum 2002; 61: 554–558.
13. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48 (11): 3253–65.
14. Lamore R 3rd, Parmar S, Patel K, Hilas O. Belimumab (Benlysta). A breakthrough therapy for systemic lupus erythematosus. PT 2012; 37(4): 212–26.
15. Halpern WG1, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006; 91 (2): 586–99.
16. Jacobi AM1, Huang W, Wang T, Freimuth W, Sanz I, Furie R et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62(1): 201–10.
17. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W et al. Belimumab Study Group.Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10(5): 109.
18. Dennis GJ. Belimumab: A BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther 2012; 91 (1): 143–9.
19. Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. Arthritis Rheum 2012; 64 (10): 3364–73.
20. Wallace DJ, Navarra S, Petri M et al. Safety profile of belimumab, a B-lymphocyte stimulator–specific inhibitor, in phase 2 and 3 clinical trials of patients with active systemic lupus erythematosus. Abstrakt. Arthritis Rheum 2010; 62 (10 Suppl.): S 491.
21. Human Genome Science BENLYSTATM (belimumab) http://www.hgsi.com/belimumab.html
22. Horák P, Tegzová D, Závada J, Olejárová M, Skácelová M, Smržová A, Žurek M. Doporučení ČRS pro léčbu nemocných se SLE. Čes Revmatol 2013; 21 (3): 110–22.
23. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W et al. Belimumab Study Group.Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10 (5): R109.
24. Wallace DJ1, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61 (9): 1168–78.
25. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377 (9767): 721–31.
26. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. BLISS-76 Study Group. Arthritis Rheum 2011; 63 (12): 3918–30.
27. Shida Y, Takahashi N, Sakamoto T, Ino H, Endo A, Hirama T. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. J Clin Pharm Ther 2014; 39 (1): 97–101.
28. http://www.gsk-clinicalstudyregister.com/compounds/belimumab#ps
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2014 Issue 4
Most read in this issue
- Belimumab in the treatment of systemic lupus erythematosus and other conditions
- Factors affecting the efficacy of anti-TNF therapy in clinical practice: experience from the ATTRA national registry